In addition, deletion of METTL3 or METTL14 increases sensitivity to interferon-γ treatment (activation of the IFN-γ pathway, which has been shown to be an important indicator of the PD-1 blockade effect [73]), which may combine immunotherapy with newly developed methyltransferase inhibitors for the treatment of CRC [74]. The gene discussed is METTL14; the disease is colorectal carcinoma.